



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/510,908	08/01/2005	Bernd Kuhn	Le A 36 031	7332
35969	7590	05/11/2009	EXAMINER	
Barbara A. Shimek			LAU, JONATHAN S	
Director, Patents & Licensing			ART UNIT	PAPER NUMBER
Bayer HealthCare LLC - Pharmaceuticals				1623
555 White Plains Road, Third Floor				
Tarrytown, NY 10591				
MAIL DATE		DELIVERY MODE		
05/11/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/510,908	KUHN ET AL.	

Examiner	Art Unit	
Jonathan S. Lau	1623	

All Participants:**Status of Application:** pending(1) Jonathan S. Lau.

(3) _____.

(2) Weiying Yang.

(4) _____.

Date of Interview: 29 April 2009**Time:** 3:10 pm**Type of Interview:**

- Telephonic
 Video Conference
 Personal (Copy given to: Applicant Applicant's representative)

Exhibit Shown or Demonstrated: Yes NoIf Yes, provide a brief description: *n/a*.**Part I.**

Rejection(s) discussed:

n/a

Claims discussed:

n/a

Prior art documents discussed:

*n/a***Part II.****SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

Applicant was directed to 37 CFR 1.55(a)(4)(ii) and MPEP 201.15 regarding the statement that the translation of the certified copy of the foreign priority document is "accurate" with regard to perfecting the claim for priority. Examiner suggested that a supplemental reply containing the statement that the translation of the certified copy of the foreign priority is accurate be submitted by fax to 571-273-8300 to facilitate the prosecution of the application.

Part III.

- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

Jonathan Lau
 Patent Examiner
 Art unit 1623

(Applicant/Applicant's Representative Signature – if appropriate)

